✨ A new milestone for Bioxodes! We have enrolled the first 8 patients in a clinical trial with BIOX-101, our candidate drug to treat intracerebral hemorrhagic stroke (ICH), a devastating type of stroke with poor prognosis, for which there currently is no treatment.
BIOX-101, derived from the saliva of the tick, halts the formation of blood clots without causing further bleeding. It also prevents the harmful neuroinflammatory reactions that often follow a stroke, by inhibiting the activation of neutrophils, a type of white blood cell that often acts as the first responders of the inflammatory system.
The Phase 2a trial, led by Prof Robin Lemmens, a world-leading stroke authority and head of clinic at the University Hospital Leuven, aims to enroll 32 patients, and we are expecting interim results for the first 16 patients by the fourth quarter of 2024.
Did you know? - Stroke is the leading cause of disability among neurological conditions worldwide. - 15 million people worldwide suffer from a stroke each year. - Of those, 5 million die, while another 5 million are left severely disabled.
Read our press release here: https://lnkd.in/e7sbQVqg
#voiceofstroke #patentprotection #bioxodes #stroke #biotech
Coordinator at The CMO Stories Series & Content Marketing Virtual Summit
1moIt sounds like the American Thoracic Society 2024 International Conference was incredibly informative and inspiring! Thank you for sharing the link to learn more about your science—it's greatly appreciated! Randy Adams, By the way, I would like to invite you to our CMO Network Podcast and share your insights in a 30-minute interview.